Table 3. Comparison of Patient Demographics and Tumor Characteristics in the NA+S Group vs the Surgery-Alone Group for the Clinical Node-Positive Patients.
Characteristic | No. (%) | P Value | ||
---|---|---|---|---|
NA+S | Surgery | Overall | ||
Overall, No. | 344 (55.7) | 274 (44.3) | 618 (100) | |
Age, mean (SD), y | 60.89 (9.44) | 67.88 (10.56) | 63.99 (10.54) | <.001 |
Q1-Q3, median (IQR) | 61.00 (54.50-68.00) | 69.50 (60.00-76.00) | 64.00 (57.00-72.00) | |
Sex | ||||
Male | 306 (89.0) | 238 (86.9) | 544 (88.0) | .43 |
Female | 38 (11.0) | 36 (13.1) | 74 (12.0) | |
Race/ethnicity | ||||
White | 335 (98.5) | 266 (98.9) | 601 (98.7) | .85 |
Black | 4 (1.2) | 2 (0.7) | 6 (1.0) | |
Other | 1 (0.3) | 1 (0.4) | 2 (0.3) | |
Facility type | ||||
Community CP | 21 (6.1) | 20 (7.5) | 41 (6.7) | .12 |
Comprehensive community CP | 135 (39.5) | 84 (31.5) | 219 (36.0) | |
Academic/research program | 186 (54.4) | 163 (61.0) | 349 (57.3) | |
Urban/rural | ||||
Metro | 253 (79.3) | 185 (74.6) | 438 (77.2) | .35 |
Urban | 54 (16.9) | 54 (21.8) | 108 (19.0) | |
Rural | 12 (3.8) | 9 (3.6) | 21 (3.7) | |
Hospital distance, mi | ||||
Mean (SD) [No.] | 42.00 (76.21) [331] | 52.58 (100.99) [249] | 46.54 (87.79) [580] | .42 |
Q1-Q3, median (IQR) | 18.70 (7.70-44.50) | 23.30 (7.20-54.70) | 19.50 (7.50-49.90) | |
Insurance | ||||
Not insured | 4 (1.2) | 4 (1.5) | 8 (1.3) | <.001 |
Private | 207 (60.5) | 87 (33.5) | 294 (48.8) | |
Medicaid | 9 (2.6) | 9 (3.5) | 18 (3.0) | |
Medicare | 119 (34.8) | 158 (60.8) | 277 (46.0) | |
Other | 3 (0.9) | 2 (0.8) | 5 (0.8) | |
Income, $ | ||||
<30 000 | 26 (7.9) | 43 (16.9) | 69 (11.8) | .004 |
30 000-34 999 | 68 (20.7) | 36 (14.2) | 104 (17.8) | |
35 000-45 999 | 89 (27.1) | 66 (26.0) | 155 (26.6) | |
>46 000 | 146 (44.4) | 109 (42.9) | 255 (43.7) | |
Education % | ||||
≥29 | 43 (13.1) | 34 (13.4) | 77 (13.2) | .72 |
20-28.9 | 79 (24.0) | 62 (24.4) | 141 (24.2) | |
14-9.9 | 91 (27.7) | 60 (23.6) | 151 (25.9) | |
<14 | 116 (35.3) | 98 (38.6) | 214 (36.7) | |
Charlson-Deyo Comorbidity Index score | ||||
0 | 260 (75.6) | 100 (67.1) | 360 (73.0) | .13 |
1 | 65 (18.9) | 36 (24.2) | 101 (20.5) | |
2 | 19 (5.5) | 13 (8.7) | 32 (6.5) | |
Grade | ||||
I | 11 (3.8) | 5 (1.9) | 16 (2.9) | .03 |
II | 111 (38.5) | 99 (38.4) | 210 (38.5) | |
III | 158 (54.9) | 154 (59.7) | 312 (57.1) | |
IV | 8 (2.8) | 8 (1.5) | ||
Disease site | ||||
Middle | 19 (5.5) | 24 (8.8) | 43 (7.0) | .12 |
Lower | 325 (94.5) | 250 (91.2) | 575 (93.0) | |
Clinical T stage | ||||
2 | 54 (15.7) | 85 (31.0) | 139 (22.5) | <.001 |
3 | 277 (80.5) | 175 (63.9) | 452 (73.1) | |
4 | 13 (3.8) | 14 (5.1) | 27 (4.4) | |
Tumor size, mm | ||||
Mean (SD) [No.] | 44.91 (30.96) [196] | 43.76 (24.95) [240] | 44.28 (27.79) [436] | .78 |
Q1-Q3, median (IQR) | 40.00 (27.00-57.50) | 40.00 (30.00-54.00) | 40.00 (28.00-55.00) | |
Inpatient stay, d | ||||
Mean (SD) [No.] | 12.16 (10.37) [291] | 16.64 (15.25) [132] | 13.56 (12.26) [423] | .002 |
Q1-Q3, median (IQR) | 9.00 (8.00-14.00) | 11.00 (8.00-18.00) | 10.00 (8.00-15.00) | |
Margins | ||||
Negative | 312 (94.0) | 210 (84.0) | 522 (89.7) | <.001 |
Positive | 20 (6.0) | 40 (16.0) | 60 (10.3) | |
Path T stage | ||||
0 | 44 (19.6) | 1 (0.4) | 45 (9.6) | <.001 |
1 | 28 (12.4) | 28 (11.5) | 56 (12.0) | |
2 | 54 (24.0) | 55 (22.6) | 109 (23.3) | |
3 | 93 (41.3) | 138 (56.8) | 231 (49.4) | |
4 | 3 (1.3) | 19 (7.8) | 22 (4.7) | |
IS | 3 (1.3) | 2 (0.8) | 5 (1.1) | |
Path N stage | ||||
0 | 147 (62.8) | 47 (19.5) | 194 (40.8) | <.001 |
1 | 87 (37.2) | 194 (80.5) | 281 (59.2) | |
No. of nodes examined | ||||
Mean (SD) [No.] | 11.06 (11.53) [329] | 14.20 (12.16) [263] | 12.46 (11.90) [592] | <.001 |
Q1-Q3, median (IQR) | 9.00 (5.00-15.00) | 12.00 (6.00-18.00) | 11.00 (5.00-16.00) | |
No. of positive nodes | ||||
Mean (SD) [No.] | 1.98 (9.69) [294] | 4.17 (7.39) [258] | 3.00 (8.75) [552] | <.001 |
Q1-Q3, median (IQR) | 0.00 (0.00-1.00) | 2.00 (1.00-5.00) | 1.00 (0.00-3.00) | |
Readmission | ||||
None | 302 (94.7) | 126 (90.0) | 428 (93.2) | .18 |
Planned | 3 (0.9) | 2 (1.4) | 5 (1.1) | |
Unplanned | 14 (4.4) | 12 (8.6) | 26 (5.7) | |
30-d Mortality | ||||
No | 337 (98.0) | 234 (86.3) | 571 (92.8) | <.001 |
Yes | 7 (2.0) | 37 (13.7) | 44 (7.2) |
Abbreviations: CP, cancer program; IQR, interquartile range;
NA+S, neoadjuvant chemoradiation plus surgery; Q, quintile.